Metreleptin
Metreleptin is a recombinant human leptin analog used to treat metabolic complications associated with generalized lipodystrophy. It works by replacing the deficient leptin hormone, helping to regulate metabolism, reduce hypertriglyceridemia, and decrease ectopic fat deposition in organs like the liver. This medication is specifically indicated for patients with congenital or acquired generalized lipodystrophy who have failed to achieve adequate metabolic control with standard therapies.
Metreleptin is a leptin replacement therapy for generalized lipodystrophy that helps control metabolic complications by restoring leptin function.
This medication carries a boxed (black box) warning — the strongest type of FDA warning. Review the full prescribing information before use.
Key facts at a glance
- ATC
- A16AA07
- RxNorm
- 1491625
- Generic
- Metreleptin
- Class
- atc-a16
- Brands
- Myalept
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- solution
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Metreleptin is indicated for the treatment of metabolic complications in patients with generalized lipodystrophy, including hypertriglyceridemia, insulin resistance, and hepatic steatosis. It is specifically approved for use in patients with congenital generalized lipodystrophy (Berardinelli-Seip syndrome) and acquired generalized lipodystrophy.
Metreleptin is a recombinant analog of human leptin that binds to and activates leptin receptors in the hypothalamus. By replacing deficient endogenous leptin, it helps regulate appetite, improves insulin sensitivity, reduces hepatic glucose production, and decreases triglyceride levels. This addresses the fundamental metabolic dysfunction caused by adipose tissue deficiency.
Metreleptin is administered via subcutaneous injection. Common adverse effects include hypoglycemia, weight loss, and injection site reactions. Patients should be monitored for anti-metreleptin antibodies and changes in immune function. It is not indicated for patients with HIV-related lipodystrophy or partial lipodystrophy.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy